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New genetic signals for lung function highlight pathways and 
chronic obstructive pulmonary disease associations across 
multiple ancestries.
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Abstract
Reduced lung function predicts mortality and is key to the diagnosis of chronic obstructive 
pulmonary disease (COPD). In a genome-wide association study in 400,102 individuals of 
European ancestry, we define 279 lung function signals, 139 of which are new. In combination, 
these variants strongly predict COPD in independent patient populations. Furthermore, the 
combined effect of these variants showed generalizability across smokers and never-smokers, and 
across ancestral groups. We highlight biological pathways, known and potential drug targets for 
COPD and, in phenome-wide association studies, autoimmune-related and other pleiotropic effects 
of lung function associated variants. This new genetic evidence has potential to improve future 
preventive and therapeutic strategies for COPD.
Editorial summary:
A genome-wide association study in over 400,000 individuals identifies 139 new signals for lung 
function. These variants can predict chronic obstructive pulmonary disease in independent, trans-
ethnic cohorts.
Introduction
Impaired lung function is predictive of mortality1 and is the key diagnostic criterion for 
chronic obstructive pulmonary disease (COPD). Globally, COPD accounted for 2.9 million 
deaths in 20162, being one of the key causes of both Years of Life Lost and Years Lived with 
Disability worldwide3. Determinants of maximally attained lung function and of lung 
function decline can influence the risk of developing COPD. Tobacco smoking is the single 
largest risk factor for COPD, although other environmental exposures and genetic makeup 
are important4,5. Genetic variants associated with lung function and COPD susceptibility can 
provide etiological insights, assisting with risk prediction, as well as drug target 
identification and validation6. Whilst there has been considerable progress in identifying 
genetic markers associated with lung function and risk of COPD4,7–19 seeking a high yield 
of associated genetic variants is key to progressing knowledge because: (i) implication of 
multiple molecules in each pathway will be needed to build an accurate picture of the 
pathways underpinning development of COPD; (ii) not all proteins identified will be 
druggable and; (iii) combining information across multiple variants can improve prediction 
of disease susceptibility.
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Through new detailed quality control and analyses of spirometric measures of lung function 
in UK Biobank and expansion of the SpiroMeta Consortium, we undertook a large genome-
wide association study of lung function. Our study entailed a near seven-fold increase in 
sample size over previous studies of similar ancestry to address the following aims: (i) to 
generate a high yield of genetic markers associated with lung function; (ii) to confirm and 
fine-map previously reported lung function signals; (iii) to investigate the putative causal 
genes and biological pathways through which lung function associated variants act, and their 
wider pleiotropic effects on other traits; and (iv) to generate a weighted genetic risk score for 
lung function and test its association with COPD susceptibility in individuals of European 
and other ancestries.
Results
139 new signals for lung function
We increased the sample size available for the study of quantitative measures of lung 
function in UK Biobank by refining the quality control of spirometry based on 
recommendations of the UK Biobank Outcomes Adjudication Working Group 
(Supplementary Note). Genome-wide association analyses of forced expired volume in 1 
second (FEV1), forced vital capacity (FVC) and FEV1/FVC were undertaken in 321,047 
individuals in UK Biobank (Supplementary Table 1) and in 79,055 individuals from the 
SpiroMeta Consortium (Supplementary Tables 2 and 3). A linear mixed model implemented 
in BOLT-LMM20 was used for UK Biobank to account for relatedness and fine-scale 
population structure (Online Methods). A total of 19,819,130 autosomal variants imputed in 
both UK Biobank and SpiroMeta were analyzed. Peak expiratory flow (PEF) was also 
analyzed genome-wide in UK Biobank and up to 24,218 samples from SpiroMeta. GWAS 
results in UK Biobank were adjusted for the intercept of LD score regression21, but 
SpiroMeta and the meta-analysis were not, as intercepts were close to 1.00 (Online 
Methods). All individuals included in the genome-wide analyses were of European ancestry 
(Supplementary Figure 1 and Supplementary Note).
To maximize statistical power for discovery of new signals, whilst maintaining stringent 
significance thresholds to minimize reporting of false positives, we adopted a study design 
incorporating both two-stage and one-stage approaches (Figure 1). In the two-stage analysis, 
99 new distinct signals, defined using conditional analyses22, were associated with one or 
more traits at P<5×10−9 (23) in UK Biobank and showed association (P<10−3) with a 
consistent direction of effect in SpiroMeta (“Tier 1” signals, Supplementary Figure 2; 
Supplementary Table 4). In the one-stage analysis, we meta-analyzed UK Biobank and 
SpiroMeta (up to 400,102 individuals) and 40 additional new distinct signals associated with 
one or more lung function traits reaching P<5×10−9 were identified (Supplementary Figure 
2, Supplementary Table 4) that were also associated with P<10−3 separately in UK Biobank 
and in SpiroMeta, with consistent direction of effect (“Tier 2” signals). An additional 323 
autosomal signals were significantly associated with one or more lung function traits in the 
meta-analysis of UK Biobank and SpiroMeta (P<5×10−9) and reached P<10−3 for 
association in only one of UK Biobank or SpiroMeta (“Tier 3” signals, Supplementary Table 
5). Analysis of chromosome X variants in 359,226 individuals (321,027 UK Biobank and 
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38,199 SpiroMeta15) gave an additional five Tier 3 signals. Only the 139 signals meeting 
Tier 1 and Tier 2 criteria were followed up further. The strength and direction of association 
of the sentinel variant (the variant in each signal with the lowest P value) for these 139 new 
signals across all 4 lung function traits are shown in Figure 2. Of the 139 signals, 131 were 
associated with at least two lung function traits at P<10−3, eight signals were unique to 
FEV1/FVC and no signals were unique to FEV1, FVC or PEF at this threshold.
We assessed whether any of these 139 signals associated with lung function could be driven 
via an underlying association with smoking behavior (Online Methods). Only rs193686 
(Supplementary Table 6) was associated with smoking behavior. Whilst rs193686 was 
associated with smoking initiation (P=9.18×10−6), the allele associated with smoking 
initiation was associated with increased lung function in never smokers (FEV1/FVC 
P=5.28×10−10, Supplementary Table 7). Therefore, this signal was retained for further 
analysis.
A total of 279 signals of association for lung function
Of 157 previously published autosomal signals of association with lung function and 
COPD3,6–18, 142 were associated at P<10−5 in UK Biobank (Online Methods, 
Supplementary Figure 3, Supplementary Table 8). Two sentinel variants (rs1689510 and 
rs11134789) were associated with smoking initiation (Supplementary Table 6), but were also 
associated with lung function in never smokers (Supplementary Table 7). SNP rs17486278 
at CHRNA5 and rs11667314 near CYP2A6 were each associated with cigarettes per day 
(Supplementary Table 6); neither were significantly associated with lung function among 
never smokers and so were excluded from further analysis. This brings the total number of 
distinct signals of association with lung function to 279 (Supplementary Table 9). None of 
these variants showed interaction with ever-smoking status (P>1.8×10−4, Online Methods, 
Supplementary Table 7). Using the effect estimates, allele frequencies and assuming a total 
heritability of 40%24,25 (Online Methods), we calculated that the 140 previously reported 
lung function signals showing association in this study (UK Biobank P<10−5) explained 
5.0%, 3.4%, 9.2% and 4.5% of the estimated heritability of FEV1, FVC, FEV1/FVC and 
PEF, respectively. The 139 new signals reported here, explain an additional 4.3%, 3.3%, 
3.9% and 3.3% of the estimated heritability, respectively.
Identification of putative causal genes
Bayesian refinement was undertaken for each signal, using the meta-analysis of UK Biobank 
and SpiroMeta, to identify the set of variants that were 99% likely to contain the underlying 
causal variant (assuming the causal variant has been analyzed, Online Methods, 
Supplementary Table 10, Supplementary Data 1 and Supplementary Data 2).
To identify putative causal genes for each signal, we identified deleterious variants and 
variants associated with gene expression (expression quantitative trait loci (eQTLs)) or 
protein levels (protein quantitative trait loci (pQTLs)) within each 99% credible set for all 
new and previously reported signals outside the HLA region (Online Methods).
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There were 25 SNPs, located in 22 unique genes, which were annotated as potentially 
deleterious (Online Methods, Supplementary Table 11). Amongst our new signals, there 
were 10 variants annotated as deleterious in 9 different genes: DOCK9 (rs117633128), 
CEP72 (rs12522955), BCHE (rs1799807), DST (rs11756977), KIAA0753 (rs2304977, 
rs9889363), LRRC45 (rs72861736), BTC (rs11938093), C2orf54 (rs6709469) and IER5L 
(rs184457). Of these, the missense variant in BCHE (rs1799807) had the highest posterior 
probability (0.996) in its respective credible set, was low frequency (minor allele frequency 
(MAF)=1.95%) and results in an amino acid change from aspartic acid (D) to glycine (G), 
known to affect the function of the encoded butyrylcholinesterase enzyme by altering 
substrate binding26. The two common missense variants in KIAA0753 were within the 
credible set of new signal rs4796334. KIAA0753, CEP72 and LRRC45 all encode proteins 
with a role in ciliogenesis or cilia maintenance27–31, and all are highly expressed in the 
airway epithelium32.
Variants in the 99% credible sets were queried in three eQTL resources to identify 
associations with gene expression in lung33–35 (n=1,111; Supplementary Table 12), blood36 
(n=4,896) and a subset of Genotype-tissue Expression (GTEx)37 tissues (max n=388, 
Online Methods). The tissues included from GTEx were lung and blood, plus nine tissues 
containing smooth muscle (Online Methods). The latter were chosen based on previous 
reports of enrichment of lung function GWAS signals in smooth muscle-containing 
tissues18,38. We identified 88 genes, implicated by 58 of the 279 signals, for which the most 
significant SNP associated with expression of that gene in the respective eQTL resource was 
within one of the 99% credible sets (Supplementary Table 13).
We checked credible set variants for association with protein levels in a pQTL study39 
comprising SNP associations for 3,600 plasma proteins (Online Methods). We found five 
proteins with a sentinel pQTL contained within our lung function credible set: ECM1, 
THBS4, NPNT, C1QTNF5 and SCARF2 (Supplementary Table 14).
In total, 107 putative causal genes were identified (Table 1), amongst which, we highlight 75 
for the first time as putative causal genes for lung function (43 implicated by a new signal 
and 32 newly implicated by a previous signal18).
Pathway analysis
We tested whether these 107 putative causal genes were enriched in gene sets and biological 
pathways (Online Methods), finding an enrichment of genes in elastic fiber and 
extracellular matrix organization pathways, and a number of gene ontologies including gene 
sets relating to the cytoskeleton and processes involved in ciliogenesis (Supplementary Table 
15). Whilst the enrichment in elastic fiber-related pathways is consistent with our previous 
study18, enrichment in these pathways was further supported in this analysis by two new 
genes, ITGAV (at a new signal) and GDF5 (a newly implicated gene for a previously 
reported signal), and by strengthened eQTL evidence for TGFB2 and MFAP2 at two 
previously reported signals. The presence of TGFB2, GDF5 and SMAD3 in our list of 107 
genes resulted in enrichment of a TGF-β superfamily signalling pathway (TGF-Core) and 
related gene ontology terms (Supplementary Table 15).
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Functional enrichment analyses
Using stratified LD-score regression40, we showed that FEV1/FVC and FVC heritability is 
significantly enriched at variants overlapping histone marks that are specific to lung, fetal 
lung, and smooth muscle-containing cell lines. SNPs that overlap with H3K4me1 marks that 
are specific to fetal lung correspond to 6.99% of the input SNPs yet explain 57.09% 
(P=2.85×10−25) and 35.84% (P=4.19×10−21) of the SNP-chip heritability for FEV1/FVC and 
FVC, respectively (Supplementary Table 16).
We also tested enrichment of (i) FEV1/FVC and (ii) FVC SNPs at DNase I hypersensitive 
site (DHS) hotspots using GARFIELD41 (Online Methods). For FEV1/FVC results, we see 
significant enrichment across most cell lines with increased fold-enrichment in fetal and 
adult lung, fetal muscle and fibroblasts (Supplementary Figure 4a). For FVC, we see similar 
broad significant enrichment without evidence of increased enrichment in a subset of tissues 
(Supplementary Figure 4b) suggesting that SNPs influencing FVC may act via more 
complex and broader developmental pathways.
We used DeepSEA42 to identify whether our signals were predicted to have a chromatin 
effect in lung-related cell lines. We identified 10 signals (including 5 new signals) for which 
the SNP with the largest posterior probability of being causal also had a significant predicted 
effect on a DHS in lung-related cells (Supplementary Table 17). This included a new signal 
near SMURF2 (rs11653958).
Drug targets 
All 107 putative causal genes were investigated for known gene-drug interactions43 
(Supplementary Table 18). We highlight two examples of new genetic signals implicating 
targets for drugs in development for indications other than COPD. One of our new signals is 
an eQTL for ITGAV. ITGAV encodes a component of the αvβ6 integrin heterodimer, which 
is inhibited by a monoclonal antibody in development for pulmonary fibrosis 
(NCT01371305) and for which the small molecule GSK3008348 (NCT03069989) is an 
antagonist44. Integrins have an emerging role as local activators of TGFβ and specifically 
the avb6 integrin heterodimer can activate latent-TGFβ45. In our study, the allele associated 
with reduced expression of ITGAV (Supplementary Table 13) was associated with increased 
lung function (Supplementary Table 9) suggesting that inhibitors of αvβ6 integrin might 
also have a beneficial effect in COPD. Another new signal is associated with expression of 
TNFSF13 (synonym APRIL), which encodes a cytokine of the TNF ligand family. Atacicept 
blocks B cell stimulation by TNFSF13 (as well as by BLyS) and reduced systemic lupus 
erythematosus disease activity in a recent Phase IIb trial46. In our study, the allele associated 
with decreased expression of TNFSF13 was associated with reduced FEV1, indicating that 
vigilance for pulmonary consequences of atacicept may be warranted.
Association with FEV1/FVC and COPD in multiple ancestries
We constructed a genetic risk score (GRS) weighted by FEV1/FVC effect sizes comprising 
all 279 sentinel variants, and tested for association with FEV1/FVC and GOLD Stage 2–4 
COPD (FEV1/FVC<0.7 and FEV1<80% predicted) in different ancestry groups in UK 
Biobank, and China Kadoorie Biobank (Online Methods, Supplementary Table 19). UK 
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Biobank participants of non-European ancestry were not included in the discovery analyses. 
The GRS was associated with a significant decrease in lung function, and corresponding 
significant increase in COPD risk in each of the independent ancestry groups (Figure 3a).
We tested for a GRS interaction with smoking in European ancestry individuals in UK 
Biobank47. No statistical interaction was seen for FEV1/FVC (interaction term −0.002 per 
SD change in GRS, 95% CI: [0.009, 0.005], P=0.532), whilst the findings for COPD were 
consistent with a slightly smaller effect of the GRS in ever-smokers (odds ratio (OR) for 
ever-smoking-GRS interaction term per SD change in GRS 0.96, 95% CI: [0.92, 0.99], 
P=0.015).
The association of the GRS with COPD susceptibility was additionally tested in five 
independent COPD case-control studies (Supplementary Table 20, Online Methods). 
Similar effect size estimates were seen across each of the 5 European ancestry studies 
(Figure 3b); in the meta-analysis of these studies (n=6,979 cases and 3,915 controls), the 
odds ratio for COPD per standard deviation of the weighted GRS was 1.55 (95% CI: [1.48, 
1.62]), P=2.87×10−75 (Supplementary Table 21). The GRS was also associated with COPD 
in individuals of African-American ancestry in COPDGene (P=8.36×10−7), albeit with a 
smaller effect size estimate, odds ratio=1.26 (95% CI: [1.15, 1.37]).
To aid clinical interpretation, we divided individuals in each of the five European ancestry 
COPD case-control studies into deciles, according to their value of the weighted GRS. The 
odds ratio for COPD in members of the highest GRS decile compared to the lowest GRS 
decile was 4.73 (95% CI: [3.79, 5.90]), P=3.00×10−43 (Figure 3c, Supplementary Table 22). 
We calculated the population attributable risk fraction (Supplementary Note) and estimated 
that the proportion of COPD cases attributable to risk scores above the first GRS decile was 
54.6% (95% CI: [50.6%, 58.4%]).
Incorporation of the GRS into a risk model already comprising available clinical information 
(age, sex, height and pack-years of smoking in COPDGene non-Hispanic Whites) led to a 
statistically significant (P=3.33×10−10), yet modest, increase in the area under the curve, 
from 0.751 to 0.771 (Supplementary Note). Based on our estimated GRS relative risk and 
absolute risk estimates of COPD48, one would expect the highest GRS risk decile group of 
smokers to have an absolute risk of developing COPD by approximately 70 years of age of 
82.4%, versus 17.4% for the lowest GRS decile (Supplementary Note).
Pleiotropy and phenome-wide association studies
As phenome-wide association studies (PheWAS) can provide evidence mimicking 
pharmacological interventions of drug targets in humans and informing drug 
development49, we undertook a PheWAS of 2,411 phenotypes in UK Biobank (Online 
Methods, Figure 4, Supplementary Table 23); 226 of the 279 sentinel variants were 
associated (false discovery rate (FDR)<1%) with one or more traits and diseases (excluding 
quantitative lung function traits). Eighty-five of the lung function signals were associated 
with standing height. In order to investigate whether the genetic association signals for lung 
function were driven by incomplete adjustment for height, we tested for correlation of 
effects on lung function in UK Biobank and height in a meta-analysis of UK Biobank and 
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the GIANT consortium for 246 of the 279 signals that had a proxy variant in GIANT50; 
there was no significant correlation (Supplementary Figure 5). Additionally, the PheWAS 
identified associations with body composition measures such as fat free mass (54 SNPs) and 
hip circumference (40 SNPs), as well as muscle strength (32 SNPs, grip strength). One 
hundred and fourteen of the 279 SNPs were associated with several quantitative measures of 
blood count, including eosinophil counts and percentages (25 SNPs). Twenty-five of our 
SNPs were also associated with asthma including 12 SNPs associated both with asthma and 
eosinophil measures (Supplementary Table 24). Eight of these SNPs were in linkage 
disequilibrium (LD, r2>0.1) with a SNP reported for association with asthma in previously 
published genome-wide association studies. We compared our observed effect sizes with 
those estimated after exclusion of all self-reported asthma cases and observed similar 
estimates (Supplementary Figure 6) suggesting that the lung function associations we report 
are not driven by asthma.
We examined the specificity of genetic associations, given the potential for this to predict 
specificity of drug target modification, and found that 53 of the 279 signals were associated 
only with lung function and COPD-related traits. In contrast, three of our 279 signals were 
associated with over 100 traits across multiple categories – among these rs3844313, a known 
intergenic signal near HLA-DQB1 was associated with 163 traits, and also had the strongest 
signal in the PheWAS, which was for association with intestinal malabsorption and celiac 
disease.
In our 279-variant weighted GRS PheWAS analysis (Supplementary Table 25), we found 
association with respiratory traits including COPD, chronic bronchitis, emphysema, 
respiratory failure, corticosteroid use and both pediatric and adult-onset asthma (Figure 5a). 
The GRS was also associated with non-respiratory traits including celiac disease, an 
intestinal autoimmune disorder (Figure 5b). These pleiotropic effects on risk of autoimmune 
diseases was further confirmed by analysis of previously reported GWAS (Online Methods, 
Supplementary Table 26) which showed overlapping single variant associations with 
Crohn’s disease, ulcerative colitis, psoriasis, systemic lupus erythematosus, IgA 
nephropathy, pediatric autoimmune disease and type 1 diabetes.
Discussion
The large sample size of our study, achieved by our refinement of the spirometry in UK 
Biobank and inclusion of the substantially expanded SpiroMeta consortium data set, has 
doubled the yield of lung function signals to 279. Fine-mapping of all new and previously 
reported signals, together with gene and protein expression analyses with improved tissue 
specificity and stringency, has implicated new genes and pathways, highlighting the 
importance of cilia development, TGF-β signalling via SMAD3, and elastic fibers in the 
etiology of airflow obstruction. Many of the genes and pathways reported here contain 
druggable targets; we highlight examples where the genetic variants mimicking therapeutic 
modulation of targets may have opposing effects on lung function. We have developed and 
applied the first weighted GRS for lung function and tested it in independent COPD case-
control studies. Our GRS shows stronger association and larger effect size estimates than a 
previous GRS in European ancestry populations18, as well as generalizability to other 
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ancestry groups. We undertook the first comprehensive PheWAS for lung function signals, 
and report genetic variants with apparent specificity of effects and others with pleiotropic 
effects that might indicate shared biological pathways between different diseases.
For the first time in a GWAS of lung function, we report an enrichment of genes involved in 
ciliogenesis (including KIAA0753, CDK2 and CEP72). Defects in primary cilia as a result 
of highly deleterious mutations in essential genes result in ciliopathies known to affect 
multiple organ systems. We found an enrichment of genes with a role in centriolar 
replication and duplication, core processes in primary and motile cilia formation. Mutations 
in KIAA0753 cause the ciliopathies Joubert Syndrome and Orofaciodigital Syndrome28. 
Reduced airway motile cilia function impacting mucus clearance is a feature of COPD, but it 
has not been clear whether this is causal or the consequence of damage by external factors 
such as smoking or infection. Our findings suggest that impaired ciliary function might be a 
driver of the disease process. We have previously shown enrichment of rare variants in cilia-
related genes in heavy smokers without airflow obstruction51.
New signals, implicating ITGAV and GDF5, as well as stronger support for TGFB2 and 
MFAP2 as likely causal genes, provide new genetic support for the importance of elastic 
fiber pathways in lung function and COPD18. The elastic fibers of the extracellular matrix 
are known to be disrupted in COPD52. As the breakdown of elastic fibers by neutrophil 
elastase leads to emphysema in individuals with alpha1-antitrypsin deficiency, we also 
assessed the association with the SERPINA1 Z allele, which was not associated with 
FEV1/FVC in our study (rs28929474, P=0.109 in UK Biobank).
Smoking and genetic risk both have important effects on lung function and COPD. For lung 
function, we found no interaction between smoking and individual variants, and for 
FEV1/FVC no interaction between smoking status and the weighted GRS. However, for 
COPD a weak smoking-GRS interaction was observed. Whilst the weighted GRS showed a 
strong association with COPD susceptibility, and a high attributable risk, we do not claim 
that this would represent an appropriate method of screening for COPD risk. Importantly, 
our findings demonstrate the high absolute risk among genetically susceptible smokers 
(82.4% by approximately 70 years of age).
We used two complementary study designs to maximize sample size for discovery and 
ensure robustness of findings by requiring independent support for association. Furthermore, 
through additional analysis of the spirometry data in UK Biobank and substantial expansion 
of the SpiroMeta consortium, we have markedly increased samples sizes to almost seven 
times those included in previous studies. As no lower MAF threshold was applied in our 
analyses, an overall threshold of P<5×10−9, as recommended for re-sequencing analyses of 
European ancestry individuals23, was applied. We identified the largest number of new 
signals in our more stringent two-stage design (“Tier 1”, 99 new signals). Amongst the 
signals that we report as “Tier 3” (and did not include in further analyses), all reached 
P<10−3 in UK Biobank and 183 met a less stringent threshold of P<0.05 in SpiroMeta.
Our study is the first to investigate genome-wide associations with PEF. PEF is determined 
by various physiological factors including lung volume, large airway caliber, elasticity of the 
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lung and expiratory muscle strength, is used for monitoring asthma, and was incorporated in 
a recently evaluated clinical score for diagnosing COPD and predicting acute exacerbations 
of COPD53. Overall, 133 of the 279 signals were also associated with PEF (P<10−5) and for 
15 signals (including 4 new signals), PEF was the most significantly associated trait. Of 
note, a signal near SLC26A9, a known cystic fibrosis modifier gene54, was highly 
significantly associated with PEF in UK Biobank (P=3.97×10−66) and nominally significant 
in SpiroMeta (P=6.93×10−3), with consistent direction of effect, but did not meet the Tier 2 
criteria. This could reflect the limited power for PEF in SpiroMeta (up to 24,218 for PEF 
compared to 79,055 for the other traits).
Examining associations of a given genetic variant with a wide range of human phenotypes is 
a valuable tool in therapeutic target validation. As in our PheWAS, it can highlight variants 
which show associations with one or more respiratory traits that might be expected to 
demonstrate greater target specificity than variants associated with many traits. Additionally, 
in some instances, association with multiple traits may indicate the relevance of drug 
repurposing. Association of a given SNP with multiple traits does not necessarily imply 
shared etiology, and further investigation is warranted. Our GRS PheWAS assesses broader 
genetic overlap between lung function and other traits and supports the evidence for some 
shared genetic determinants with autoimmune diseases.
In summary, our study has doubled the number of signals for lung function and provides 
new understanding and resources of utility for the development of therapeutics. The 279-
variant GRS we constructed was associated with a 4.73-fold increased relative risk of 
moderate-severe COPD between highest and lowest deciles, such that one would expect over 
80% of smokers in the highest genetic risk decile to develop COPD. The GRS was also 
predictive of COPD across multiple ancestral groups. Our PheWAS highlights both expected 
and unexpected associations relevant to respiratory and other systemic diseases. 
Investigating the nature of the pleiotropic effects of some of these variants will be of benefit 
for drug target identification and validation.
Online Methods
Study Design Overview and rationale
For the two-stage approach, we first selected distinct signals of association (defined using 
conditional analyses) with one or more traits achieving P<5×10−9 in UK Biobank only 
(maximum n=321,047). A threshold of P<5×10−9 was selected to maximize stringency and 
for consistency with currently recommended genome-wide significance thresholds for re-
sequencing analyses of European ancestry individuals23. We reported as new those signals 
which additionally met P<10−3 in SpiroMeta (N effective>70% of n up to 79,055; see 
Supplementary Note and Supplementary Figure 7 for power calculations), with consistent 
directions of effect. We term these “Tier 1” signals, as they meet our highest level of 
stringency. Methods for conditional analyses and determining novelty are described below.
For the one-stage approach, we selected distinct signals of association (defined using 
conditional analyses) with one or more traits reaching P<5×10−9 in the meta-analysis of UK 
Biobank and SpiroMeta (maximum n=400,102), reporting as new those with a consistent 
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direction of effect that additionally met P<10−3 in both UK Biobank and SpiroMeta. We 
term these signals “Tier 2”, as they meet our second-highest level of stringency.
All signals meeting either set of criteria described above, and that had not been previously 
published, were reported as new association signals for lung function. Signals that reached 
P<5×10−9 in the meta-analysis of UK Biobank and SpiroMeta, had a consistent direction of 
effect in UK Biobank and SpiroMeta, but that did not reach P<10−3 in both UK Biobank and 
SpiroMeta are presented as “Tier 3”, and were not included in further analyses.
Data for chromosome X were available for 321,027 European individuals in UK Biobank 
and 38,199 individuals from SpiroMeta (1000 Genomes Project Phase 1 imputation).55
Please see the ‘Life Sciences Reporting Summary’.
UK Biobank
The UK Biobank resource is described elsewhere (see URLs). Individuals were selected for 
inclusion in this study if they: (i) had complete data for age, sex, height and smoking status; 
(ii) had spirometry meeting quality control requirements (based on analyses of acceptability, 
reproducibility and blow curve metrics; Supplementary Note); (iii) had genome-wide 
imputed data and; (iv) were of European ancestry based on genetic data (Supplementary 
Note; Supplementary Figure 1). Genotyping was undertaken using the Affymetrix Axiom® 
UK BiLEVE and UK Biobank arrays13. Genotypes were imputed to the Haplotype 
Reference Consortium panel56 (Supplementary Note), and retained if minor allele count≥3 
and imputation quality (info)>0.5. In total, 321,047 individuals were included in our 
analyses (Supplementary Table 1).
Residuals from linear regression of each trait (FEV1, FVC, FEV1/FVC and PEF) against 
age, age2, sex, height, smoking status (ever/never) and genotyping array were ranked and 
inverse-normal transformed, giving normally distributed Z-scores. These Z-scores were used 
for genome-wide association testing under an additive genetic model using BOLT-LMM 
v2.320. Principal components were not included as BOLT-LMM uses a linear mixed model 
to account for relatedness and fine-scale population structure.
Linkage disequilibrium (LD) score regression implemented in LDSC21 was used to estimate 
test statistic inflation due to confounding. Genomic control was applied, adjusting test 
statistics by LD score regression intercepts: 1.12 for FEV1, 1.14 for FVC, 1.19 for 
FEV1/FVC and 1.13 for PEF (Supplementary Figure 8; Supplementary Table 27), 
acknowledging that this might be over-conservative for UK Biobank.
SpiroMeta consortium
The SpiroMeta consortium meta-analysis comprised a total of 79,055 individuals from 22 
studies. Thirteen studies (n=21,436) were imputed to the 1000 Genomes Project Phase 1 
panel55 (B58C, BHS1&2, three Croatian studies [CROATIA-Korcula, CROATIA-Split and 
CROATIA-Vis], Health 2000, KORA F4, KORA S3, LBC1936, NSPHS, ORCADES, 
SAPALDIA and YFS) and 9 studies (n=61,682) were imputed to the Haplotype Reference 
Consortium (HRC) panel57 (EPIC [obese cases and population-based studies], GS:SFHS, 
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NFBC1966, NFBC1986, PIVUS, SHIP, SHIP-TREND, UKHLS and VIKING). See 
Supplementary Tables 2 and 3 for abbreviation definitions, study characteristics, and details 
of genotyping platforms, imputation panels and methods). Measurements of spirometry for 
each study are described in the Supplementary Note.
In each study, linear regression models were fitted for each trait (FEV1, FEV1/FVC, FVC 
and where available, PEF), with adjustment for age, age2, sex and height. For studies with 
unrelated individuals, models were fitted separately in ever and never smokers, with 
additional adjustment for ancestral principal components. Studies with related individuals 
fitted mixed models in all individuals to account for relatedness, with ever smoking status as 
a covariate.
In all studies, residuals were rank-based inverse normal transformed and used as the 
phenotype for association testing, under an additive genetic model (Supplementary Table 3).
In the study-level results, variants were excluded if they had a low minor allele count (MAC) 
(Supplementary Table 3) or imputation quality (info)<0.3. In studies of unrelated 
individuals, ever and never smokers’ results were combined using inverse-variance weighted 
meta-analysis. Genomic control was applied to all study-level results, before combining 
results across all studies using inverse-variance weighted meta-analysis. LD score regression 
intercepts for the meta-analysis were close to 1.00 (Supplementary Figure 8; Supplementary 
Table 27), therefore genomic control was not applied.
Meta-analyses
A total of 19,819,130 variants (imputed or genotyped) in both UK Biobank and SpiroMeta 
were meta-analyzed, using inverse-variance weighted fixed effect meta-analysis. No further 
genomic control was applied as LD score regression intercepts were close to 1.00 
(Supplementary Table 27).
Selection of new signals using conditional analyses
All SNPs ±1 Mb were extracted around each sentinel variant. We performed stepwise 
conditional analysis to select independently associated SNPs within each 2-Mb region, using 
GCTA58. LD was estimated for UK Biobank from the same individuals used in discovery, 
and for SpiroMeta, from an unrelated subset of 48,943 UK Biobank individuals18. 
Secondary signals identified within each 2-Mb region were required to meet Tier 1 or Tier 2 
criteria (described above) after conditioning on the primary sentinel variant. A combined list 
of distinct lung function signals was then made across the four phenotypes, FEV1, FVC, 
FEV1/FVC and PEF, as follows: where sentinel variants for 2 signals for different 
phenotypes were in high LD (r2>0.5), we retained the most significant variant; where 2 
signals were in moderate LD (0.1>r2>0.5), we retained variants if, after conditional analysis, 
they still met the Tier 1 or Tier 2 threshold; for signals in low LD (r2<0.1) we retained both 
variants. We then used the same criteria to identify a subset of new signals which were 
distinct from previously published independent signals (see below).
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Assessment of previously reported lung function signals
We identified 184 autosomal signals from previous GWAS of lung function and 
COPD1,4–14. After LD pruning (only keeping signals with LD of r2<0.1), we removed 24 
non-independent SNPs, leaving 160 previously reported independent signals. Of 6 
previously reported signals in the HLA region, we included only the 3 independent lung 
function HLA signals reported from conditional analysis using all imputed HLA 
genotypes18: AGER (rs2070600), HLA-DQB1 (rs114544105) and near ZNF184 
(rs34864796), leaving 157 autosomal signals.
We confirmed association of previously reported signals in our data if they met any of three 
criteria: (i) the previously reported sentinel was associated (P<10−5) with any lung function 
trait in UK Biobank; (ii) a proxy for the previously reported sentinel with r2>0.5 was 
associated (P<10−5) with any lung function trait in UK Biobank; (iii) a proxy for the 
previously reported sentinel with r2>0.1 was associated with any lung function trait meeting 
tier 1 or tier 2 criteria (Supplementary Figure 3).
Effect on COPD susceptibility – genetic risk score in multiple ancestries
To test association of all lung function signals with COPD susceptibility, we constructed a 
279-variant weighted GRS comprising the 139 novel and 140 previously reported signals; 
we used the previously reported sentinel SNP for published signals. Weights were derived 
using the FEV1/FVC decreasing (generally COPD risk increasing) alleles. For previously 
reported signals (n=140), effect sizes from UK Biobank were used as weights for the 94 
signals that were not discovered using UK Biobank data. Weights were taken from 
SpiroMeta for 46 signals where UK Biobank was included in the discovery of those signals. 
For novel signals, weights were taken from SpiroMeta for two-stage (tier 1) signals (n=99), 
and the smallest absolute effect size from either UK Biobank or SpiroMeta was used for 
one-stage (tier 2) signals (n=40) (Supplementary Table 28). This approach was taken in 
order to derive conservative weights, thus reducing the likelihood of bias by winner’s curse. 
For the weighted GRS the number of risk alleles at each variant was multiplied by its 
weight.
The GRS was first calculated in unrelated individuals (KING kinship coefficient of<0.0884) 
within 6 ancestral groups of UK Biobank: Europeans, South Asians, Africans, Chinese, 
Mixed African and Europeans, and Mixed Other (total sample of unrelated individuals 
across six ancestries: 323,001) using PLINK. Weights and alleles were as described above. 
COPD was defined as FEV1/FVC<0.7 and FEV1<80% predicted, i.e. GOLD stage 2–4 
categorization. Associations with the GRS were then tested using COPD (in ancestral groups 
with at least 100 COPD cases) and FEV1/FVC as the outcomes.
We also calculated the GRS in individuals from the China Kadoorie Biobank (CKB). Four of 
the 279 SNPs were unavailable in CKB (rs1800888, rs56196860, rs72724130 and 
rs77672322), and for 12 SNPs, proxies were used (minimum r2=0.3). Analyses were 
undertaken in all COPD GOLD stage 2–4 cases (FEV1/FVC<0.7 and FEV1<0.8 of the 
predicted value: 6,013 cases and 69,567 controls), against an unbiased set of population 
controls. The GRS was also tested for association with FEV1/FVC in CKB (n=72,796).
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Logistic regression of COPD case-control status with the GRS in UK Biobank and China 
Kadoorie Biobank assumed an additive genetic effect and was adjusted for age, age2, sex, 
height, and smoking (Supplementary Table 19). Ten principal components were included in 
UK Biobank analyses. In China Kadoorie Biobank, analyses were stratified by geographical 
regions, then meta-analyzed using an inverse-variance fixed effect model. Linear models 
assessing the association with FEV1/FVC were fitted using the transformed outcome used in 
the main GWAS analysis.
We then tested association in 5 European-ancestry COPD case-control studies: COPDGene 
(Non-Hispanic White Population) (3,068 cases, 2,110 controls), ECLIPSE (1,713 cases, 147 
controls), GenKOLS (836 cases, 692 controls), NETT-NAS (374 cases, 429 controls) and 
SPIROMICS (988 cases, 537 controls) (Supplementary Table 20). We also tested this GRS 
in the COPDGene African American population study (910 cases, 1,556 controls). Logistic 
regression models using COPD as outcome and the GRS as exposure were adjusted for age, 
age2, sex, height, and principal components (Supplementary Table 21, Supplementary Figure 
9). Single variant associations of the 279 SNPs with COPD are in Supplementary Table 29.
Next, we divided individuals in the external COPD case-control studies into deciles, 
according to their values of the weighted GRS (undertaken separately by study group). For 
each decile, logistic models were fitted, comparing the risk of COPD for members of the 
decile compared to those in the lowest decile (i.e. those with lowest values of the weighted 
GRS). Covariates were as for COPD analyses. Results were combined across European-
ancestry study groups by fixed effect meta-analysis (Supplementary Table 22).
Effects on smoking behavior
As our discovery GWAS in UK Biobank was adjusted for ever smoking status, and not for 
pack years of smoking (this information was missing for 32% of smokers), we evaluated 
whether any lung function association signals might be driven by an association with 
smoking behavior, by testing for association with smoking initiation (123,890 ever smokers 
vs. 151,706 never smokers) and cigarettes per day (n=80,015) in UK Biobank (see 
Supplementary Note). We also tested for association with lung function in never smokers 
only (n=173,658). We excluded signals associated with smoking behavior (Supplementary 
Table 6) but not with lung function in never smokers.
Smoking interaction
For associated variants (new and previously reported), we repeated association testing for 
lung function separately in UK Biobank and SpiroMeta (up to 176,701 ever smokers and 
197,999 never smokers), and tested for an interaction effect with smoking using the Welch 
test (Supplementary Note). A threshold of P<1.79×10−4 (Bonferroni corrected for 279 tests) 
indicated significance.
We also tested for interaction between the weighted GRS and smoking, within 303,619 
unrelated individuals of European ancestry in UK Biobank, using COPD and FEV1/FVC as 
outcomes (FEV1/FVC was pre-adjusted for age, age2, sex, and height, and the residuals 
transformed as per the main GWAS analysis). For COPD (defined as FEV1/FVC<0.7, and 
FEV1<80% predicted) a logistic model was fitted:
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COPD ~ genotyping array + 10 principal components + age + age2 + sex + height + 
smoking status + weighted risk score + (smoking status × weighted risk score).
For FEV1/FVC, a linear model was fitted:
FEV1/FVC ~ genotyping array + 10 principal components + smoking status + 
weighted risk score + (smoking status x weighted risk score).
Proportion of variance explained
We calculated the proportion of variance explained by the previously reported (n=140) and 
new variants (n=139) associated with lung function using the formula:
∑
i = 1
n
2 f i 1 − f i βi
2
V
where n is the number of variants, fi and βi are the frequency and effect estimate of the i’th 
variant, and V is the phenotypic variance (always 1 as our phenotypes were inverse-normal 
transformed). We used the same conservative effect estimates (β) used as GRS weights for 
the 279 GRS variants, derived from either UK Biobank or SpiroMeta effect estimates 
(described above). Our previously published estimate of proportion of variance explained18 
used UK Biobank effect estimates. We assumed a heritability of 40%24,25 to estimate the 
proportion of additive polygenic variance.
Fine-mapping
A Bayesian method59 was used to fine-map lung-function-associated signals to the set of 
variants that were 99% likely to contain the underlying causal variant (assuming that the 
causal variant was analyzed). This was undertaken for new signals and for previously 
reported signals reaching P<10−5 in UK Biobank. For previously reported signals, the 
sentinel variant from the current UK Biobank analysis was used, instead of the previously 
reported variant. We used a value of 0.04 for the prior W in the approximate Bayes factor 
formula60. Effect sizes and standard errors for fine-mapping were obtained from inverse-
variance weighted meta-analysis of UK Biobank and SpiroMeta (maximum n=400,102). 
Signals in the HLA region were not included.
Implication of potentially causal genes
Annotation of deleterious variants—Variants in the 99% credible sets were checked 
for predicted functional effect if they were annotated as “exonic”, “splicing”, 
“ncRNA_exonic”, “5’-UTR” or “3’-UTR” (untranslated region) by ANNOVAR61. We then 
used SIFT, PolyPhen-2 (implemented using the Ensembl GRCh37 Variant Effect Predictor, 
see URLs) and FATHMM62 to annotate missense variants, and CADD (also implemented 
using VEP) to annotate non-coding variation. Variants were annotated as deleterious if they 
were labelled ‘deleterious’ by SIFT, ‘probably damaging’ or ‘possibly damaging’ by 
PolyPhen-2, ‘damaging’ by FATHMM (specifying the ‘Inherited Disease’ option of the 
‘Coding Variants’ method, and using the ‘Unweighted’ prediction algorithm) or had a 
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CADD scaled score ≥2018. The union of the four methods was taken to establish the number 
of potentially deleterious variants and their unique genes.
Gene expression and protein levels—At 276 of 279 (3 HLA signals excluded) 
signals, the sentinel variant and 99% credible set59 were used to query three eQTL 
resources: lung eQTL (n=1,111)13, blood eQTL (n=4,896)63 and GTEx (V7; with maximum 
n=388, depending on tissue: ‘Artery Aorta’ (n=267), ‘Artery Coronary’ (n=152), ‘Artery 
Tibial’ (n=388), ‘Colon Sigmoid’ (n=203), ‘Colon Transverse’ (n=246), ‘Esophagus 
Gastroesophageal Junction’ (n=213), ‘Esophagus Muscularis’ (n=335), ‘Lung’ (n=383), 
‘Small Intestine Terminal Ileum’ (n=122), ‘Stomach’ (n=237), and ‘Whole Blood’ 
(n=369))64, and one blood pQTL resource (n=3,301)39.
A gene was classified as a ‘putative causal gene’ if the sentinel SNP or any SNP in the 
respective 99% credible set was associated with expression of this gene or its protein levels 
(FDR<5% for eQTL, P<5.03×10−8 for pQTL [276 tests at 3,600 proteins]) and if the GWAS 
sentinel SNP or any SNP in the respective 99% credible set was the variant most strongly 
associated with expression of the respective gene or level of the respective protein (i.e. the 
sentinel eQTL/pQTL SNP) in one or more of the eQTL and pQTL data sets.
Pathway analysis
We tested for enrichment of genes identified via functional annotation, gene expression or 
protein level analyses in pathway and gene set ontology databases using ConsensusPathDB.
65
 Pathways or gene sets represented entirely by genes implicated by the same association 
signal were excluded. Gene sets and pathways with FDR<5% are reported.
Functional enrichment analyses
We carried out stratified LD score regression to identify significant enrichment of 
heritability at variants overlapping histone marks (e.g. H3K4me1, H3K4me3) specific to 
lung, foetal lung, and smooth muscle-containing (e.g. colon, stomach) cell lines, using 
methods specified by Finucane et al.40
We separately selected FEV1/FVC and FVC associated SNPs passing two thresholds 
(P<5×10−5 and P<5×10−9 in the meta-analysis) as input to GARFIELD41 to test for 
enrichment of our signals for 424 DHS hotspot annotations derived from 55 different tissues 
in the RoadMap Epigenomics and ENCODE projects.
Using DeepSEA42, we analyzed all SNPs in the 99% credible set for predicted chromatin 
effects. We reported effects for any chromatin effect and lung-related cell line with an E-
value<0.05 (i.e. the expected proportion of SNPs with a larger predicted effect based on 
empirical distributions of predicted effects for 1000 Genomes SNPs) and an absolute 
difference in probability of>0.1 (threshold for “high confidence”) between the reference and 
alternative allele.
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Drug targets
Genes identified as potentially causal using eQTL, pQTL or variant annotation were 
interrogated against the gene-drug interactions table of the Drug-Gene Interactions Database 
(DGIDB) (see URLs). Drugs were mapped to CHEMBL IDs (see URLs), and indications 
(MeSH headings) were added.
Phenome-wide association studies
To identify whether the 279 signals were associated with other traits and diseases, the 
weighted GRS was calculated in up to 379,337 UK Biobank samples, and a phenome-wide 
association study (PheWAS) was performed, with the GRS as the exposure. Traits included 
UK Biobank baseline measures (from questionnaires and physical measures), self-reported 
medication usage, and operative procedures, as well as those captured in Office of 
Population Censuses and Surveys codes from the electronic health record. We also included 
self-reported disease variables and those from hospital episode statistics (ICD-10 codes 
truncated to three-character codes and combined in block and chapter groups), combining 
these where possible to maximize power. The GRS analysis included 2,453 traits, and the 
single-variant analysis contained 2,411 traits (traits with>200 cases were included for the 
single-variant PheWAS, whereas traits with>50 cases were included in the GRS PheWAS). 
Analyses were conducted in unrelated European-ancestry individuals (KING kinship 
coefficient <0.0442), and were adjusted for age, sex, genotyping array, and ten principal 
components. Logistic and linear models were fitted for binary and quantitative outcomes, 
respectively. False discovery rates were calculated according to the number of traits in the 
GRS and single-variant PheWAS (2,453 or 2,411, respectively).
In addition, the sentinel variants 99% credible set variants were queried against the GWAS 
catalog66 (see URLs) and GRASP67 (see URLs) for associations at P<5×10−8. Associations 
relating to methylation, expression, metabolite or protein levels, as well as lung function and 
COPD, were not included.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: Study design
Tier 1 signals had P<5×10−9 in UK Biobank and P<10−3 in SpiroMeta with consistent 
direction of effect.
Tier 2 signals had P<5×10−9 in the meta-analysis of UK Biobank and SpiroMeta with 
P<10−3 in UK Biobank and P<10−3 in SpiroMeta with consistent directions of effect. 
Signals with P<5×10−9 in the meta-analysis of UK Biobank and SpiroMeta, and that had 
consistent directions of effect but did not meet P<10−3 in both cohorts were reported as Tier 
3.
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Figure 2: Strength and direction of association across four lung function traits for 139 novel 
signals:
Signals are in chromosome and genomic position order from top to bottom then left to right. 
Red indicates a decrease in the lung function trait; blue indicates an increase. All effects are 
aligned to the allele associated with decreased FEV1/FVC, hence the FEV1/FVC column is 
only red or white. P-values are from the meta-analysis of UK Biobank and SpiroMeta 
(n=400,102). The scale points are thresholds used for (i) confirmation in 2-stage analysis 
and 1-stage analysis (P<10−3); (ii) confirmation of association of previous signals (P<10−5); 
(iii) signal selection in 2-stage and 1-stage analysis (P<5×10−9); capped at (P<10−20). FEV1, 
forced expired volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow
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Figure 3: Association of weighted genetic risk score (wGRS) with COPD and FEV1/FVC.
a. Association of the wGRS with FEV1/FVC and COPD in UK Biobank (UKB) and China 
Kadoorie Biobank (CKB) (Supplementary Table 19). Left-hand axis: standard deviation 
(SD) change in FEV1/FVC per SD increase in wGRS (light grey bars, N=total sample size). 
Right-hand axis: the translation of this effect to COPD (GOLD stage 2–4) odds ratio (OR) 
per SD increase in wGRS in the same individuals for UKB ancestries with >100 COPD 
cases (dark grey bars, N=number of cases + number of controls. Whiskers represent 95% 
confidence intervals. Some variants in the wGRS were discovered in UKB Europeans, 
therefore UKB Europeans are shown for reference only (far left, ‘Discovery sample’). All 
other ancestral groups are independent to UKB Europeans.
b. OR for COPD per SD increase in wGRS in six study groups. COPD was defined using 
GOLD 2–4 criteria (Supplementary Table 21: means and SDs of risk scores). The vertical 
black line indicates the null effect (OR=1). The point estimate of each study is represented 
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by a box proportional to study weight; whiskers represent 95% confidence intervals. The 
diamond represents a fixed effect meta-analysis of the five European-ancestry groups, the 
width of which represents the 95% confidence interval (I2 statistic=0).
c. OR for COPD according to deciles of the wGRS, with decile 1 (the 10% of individuals 
with the lowest GRS) as the reference group. Each point represents a meta-analysis of 
results for a given comparison (e.g. decile 2 vs reference, decile 3 vs reference, etc.) in five 
external European-ancestry study groups (COPDGene, ECLIPSE, GenKOLS, SPIROMICS, 
NETT-NAS). Deciles were calculated and models were run in each group separately. Error 
bars show 95% confidence intervals (Supplementary Table 22).
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Figure 4: Individual PheWAS with 279 variants (traits passing FDR 1% threshold)
Separate association of 279 variants with 2,411 traits (FDR<1%) in UK Biobank (n up to 
379,337). In each category, the trait with the strongest association, i.e. highest –log10(FDR), 
is shown first, followed by other traits in that category in descending order of –log10(FDR). 
Categories are colour-coded, and outcomes are denoted with a circular or triangular point, 
according to whether they were coded as binary or quantitative. The top association per-
category is labelled with its rsID number, and a plain English label describing the trait. The 
letter at the beginning of each label allows easy cross-reference with the categories labelled 
in the legend. Zoomed in versions of each category with visible trait names and 
directionality are available in Supplementary Figure 10. These plots have signed log10(FDR) 
values, where a positive values indicates that a positive SNP-trait association is concordant 
with the risk allele for reduced lung function (as measured by lower FEV1/FVC). Tabulated 
results of all SNP-trait PheWAS associations associated at an FDR of<1% are available in 
Supplementary Table 23.
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Figure 5: PheWAS with genetic risk score (traits passing FDR 1% threshold)
Association of 279 variant weighted genetic risk score with 2,453 traits (FDR<1%) in UK 
Biobank (n up to 379,337). In each panel, the category with the strongest association, i.e. 
highest –log10(FDR), is shown first, followed by all other associations in that category, 
ordered by descending order of –log10(FDR). Sample sizes varied across traits and are 
available in Supplementary Table 25, along with the full summary statistics for each 
association, plus details of categorisation and plain English labels for each trait. Trait 
categories are colour coded, and outcomes are denoted with a circular or triangular point, 
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according to whether they were coded as binary or quantitative. The sign of the log10(FDR) 
value is positive where an increase in the risk score (i.e. greater risk of COPD, reduced lung 
function) is associated with a positive effect estimate for that trait. *QC refers to spirometry 
passing ERS/ATS criteria. SR=self-report; HES=Hospital Episode Statistics.
a. Associations with respiratory traits.
b.Associations with all other traits. ENT=Ear, Nose and Throat; FBC=Full Blood Count.
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